Trevi Therapeutics’ (TRVI) Buy Rating Reaffirmed at B. Riley

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reaffirmed by analysts at B. Riley in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $6.00 target price on the stock. B. Riley’s price target would indicate a potential upside of 101.34% from the company’s previous close.

Several other research firms have also issued reports on TRVI. Rodman & Renshaw began coverage on shares of Trevi Therapeutics in a research report on Thursday, June 13th. They issued a “buy” rating and a $7.00 price objective for the company. HC Wainwright began coverage on shares of Trevi Therapeutics in a report on Friday, August 30th. They set a “buy” rating and a $6.00 price target for the company. Raymond James began coverage on shares of Trevi Therapeutics in a report on Friday, August 30th. They set an “outperform” rating and a $9.00 price target for the company. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. Finally, Leerink Partners began coverage on shares of Trevi Therapeutics in a report on Monday, September 9th. They set an “outperform” rating and a $7.00 price target for the company. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $7.43.

Trevi Therapeutics Stock Down 1.3 %

Shares of Trevi Therapeutics stock traded down $0.04 during trading hours on Monday, hitting $2.98. The company’s stock had a trading volume of 20,193 shares, compared to its average volume of 258,359. Trevi Therapeutics has a 1-year low of $0.97 and a 1-year high of $4.00. The business has a fifty day moving average of $3.04 and a 200 day moving average of $2.91. The company has a market capitalization of $209.90 million, a PE ratio of -8.76 and a beta of 0.97.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same period in the prior year, the business earned ($0.07) EPS. On average, sell-side analysts anticipate that Trevi Therapeutics will post -0.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 10,981 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the completion of the transaction, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at $644,205.26. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Thomas Sciascia sold 18,660 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $2.76, for a total value of $51,501.60. Following the transaction, the insider now directly owns 220,315 shares in the company, valued at approximately $608,069.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jennifer L. Good sold 10,981 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total transaction of $33,162.62. Following the completion of the transaction, the chief executive officer now owns 213,313 shares in the company, valued at approximately $644,205.26. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,355 shares of company stock valued at $116,663 in the last ninety days. Corporate insiders own 24.37% of the company’s stock.

Institutional Trading of Trevi Therapeutics

Several hedge funds have recently bought and sold shares of TRVI. Frazier Life Sciences Management L.P. lifted its position in Trevi Therapeutics by 7.3% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company’s stock valued at $9,891,000 after purchasing an additional 500,000 shares during the last quarter. Opaleye Management Inc. lifted its position in Trevi Therapeutics by 48.6% in the 4th quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company’s stock valued at $3,397,000 after purchasing an additional 829,100 shares during the last quarter. Oppenheimer & Co. Inc. bought a new stake in Trevi Therapeutics in the 1st quarter valued at about $208,000. Vanguard Group Inc. lifted its position in Trevi Therapeutics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock valued at $7,948,000 after purchasing an additional 60,249 shares during the last quarter. Finally, Propel Bio Management LLC bought a new stake in Trevi Therapeutics in the 1st quarter valued at about $897,000. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.